HanchorBio Clears FDA Hurdle for Novel Trispecific Cancer Therapy
Event summary
- FDA cleared HanchorBio's IND application for HCB303 on October 5, 2026.
- HCB303 is a trispecific immunotherapy targeting TIGIT/PVR, PD-L1/PD-1, and SIRPα/CD47 pathways.
- Phase 1 trial will begin as a multi-regional, dose-escalation study in advanced solid tumor patients.
- HanchorBio's second trispecific immunotherapy to enter clinical development.
The big picture
HanchorBio's FDA clearance for HCB303 represents a strategic milestone in the trispecific immunotherapy space, positioning the company as a key player in developing next-generation cancer treatments. The simultaneous targeting of multiple immune pathways could address limitations of current monoclonal antibody therapies, potentially offering more comprehensive tumor suppression. This development comes amid growing industry interest in combination immunotherapies that engage both innate and adaptive immune responses.
What we're watching
- Clinical Efficacy
- Whether HCB303's differentiated TIGIT-Fc strategy translates into meaningful clinical benefits for patients.
- Development Pace
- The speed at which HanchorBio can advance both HCB301 and HCB303 through clinical trials.
- Platform Potential
- How effectively HanchorBio's FBDB™ platform can generate additional mechanistically distinct therapeutics.
Related topics